At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 161 enrolled
Drug / intervention
D-2570 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating D-2570 and Placebo for Plaque Psoriasis. Completed, enrolled 161 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartJan 2024
First PostedFeb 2024
Primary CompletionNov 2024
TodayJul 2026
First PostedFeb 26, 2024
Enrollment StartJan 31, 2024
Primary CompletionNov 1, 2024
TodayJul 1, 2026
Enrollment to primary: 9 monthsPosted 2.3 years ago
Interventions
D-2570drug
Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group 1, group 2, group 3 or placebo group.
Placebodrug
Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group 1, group 2, group 3 or placebo group.